Yabao Pharmaceutical Group (600351) Fundamentals 2026 — P/E 14.4x, Revenue Analysis | SniperIQ
Yabao Pharmaceutical Group (600351) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥4.5B, trading at ¥6.56 on the SHH. This SniperIQ fundamentals page covers Yabao Pharmaceutical Group's valuation (P/E 14.4x, P/B 1.6x), profitability (net margin 14.5%), revenue (¥2.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yabao Pharmaceutical Group's market cap?
Yabao Pharmaceutical Group (600351) has a market capitalization of approximately ¥4.5B, trading at ¥6.56 on the SHH. Market cap moves with the live share price.
What is Yabao Pharmaceutical Group's P/E ratio?
Yabao Pharmaceutical Group's trailing twelve-month P/E ratio is 14.4x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Yabao Pharmaceutical Group?
Yabao Pharmaceutical Group runs a net profit margin of 14.5%, a gross margin of 52.1%, and an operating margin of 12.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yabao Pharmaceutical Group generate?
Yabao Pharmaceutical Group reported revenue of ¥2.2B for fiscal year 2025, with net income of ¥320M and earnings per share (EPS) of 0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yabao Pharmaceutical Group pay a dividend?
Yabao Pharmaceutical Group offers a trailing dividend yield of about 5.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Yabao Pharmaceutical Group financially healthy?
Yabao Pharmaceutical Group carries a debt-to-equity ratio of 0.01x and a current ratio of 3.92x, with a market beta of 0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yabao Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yabao Pharmaceutical Group (600351) the key facts are: market cap ¥4.5B, P/E 14.4x, revenue ¥2.2B, 52-week range 5.6-8.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Yabao Pharmaceutical Group's full fundamentals live
Get Yabao Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.